{"id":397171,"date":"2020-12-10T07:48:09","date_gmt":"2020-12-10T12:48:09","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=397171"},"modified":"2020-12-10T07:48:09","modified_gmt":"2020-12-10T12:48:09","slug":"creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\/","title":{"rendered":"Creative Medical Technology Holdings files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz\u00ae Cellular Immunotherapy"},"content":{"rendered":"<div class=\"xn-newslines\">\n<h2 class=\"xn-hedline\">Clinical Stage Cell Therapy Company Reports Concurrent Modulation of T Regulatory Cells and Tolerogenic Dendritic Cells using Adoptive Cellular Therapy<\/h2>\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"xn-location\">PHOENIX<\/span>, <span class=\"xn-chron\">Dec. 10, 2020<\/span> \/PRNewswire\/ &#8212;\u00a0Creative Medical Technology Holdings trading under the ticker symbol CELZ announced today its patent filing based on data covering utilization of the Company&#8217;s ImmCelz<sup><span>\u00ae<\/span><\/sup> product at generating what is termed in the field of immunology as &#8220;infectious tolerance.&#8221;\u00a0 <\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/926061\/Creative_Medical_Technology_Holdings_Inc_Logo.html\" target=\"_blank\" rel=\"nofollow noopener noreferrer\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/926061\/Creative_Medical_Technology_Holdings_Inc_Logo.jpg\" title=\"Creative Medical Technology Holdings, Inc. Logo (PRNewsfoto\/Creative Medical Technology Hol)\" alt=\"Creative Medical Technology Holdings, Inc. Logo (PRNewsfoto\/Creative Medical Technology Hol)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>Using an animal model of rheumatoid arthritis, investigators demonstrated administration of ImmCel<sup><span>\u00ae<\/span><\/sup> protected mice from immunologically mediated joint damage. Importantly, cells from treated mice were able to reverse disease when transferred to arthritic mice. Detailed scientific analysis revealed that ImmCelz<sup><span>\u00ae<\/span><\/sup> administration caused generation of T regulatory cells and tolerogenic dendritic cells.\u00a0 Both of these cell types have previously been described to possess ability to suppress autoimmunity.<\/p>\n<p>&#8220;In 2003, Dr. <span class=\"xn-person\">Weiping Min<\/span> from the <span class=\"xn-org\">University of Western Ontario<\/span> and myself published a paper describing the Tolerogenic Loop, in which we were able to perform fully mis-matched cardiac transplants without need for long term immune suppression<sup>1<\/sup>.&#8221; Said Dr. <span class=\"xn-person\">Thomas Ichim<\/span>, Chief Scientific Officer of the Company.\u00a0 &#8220;We are extremely enthusiastic to discover that ImmCelz<sup><span>\u00ae<\/span><\/sup>, which is a personalized immunotherapy can induce similar biological processes and in this case suppress autoimmunity.&#8221;<\/p>\n<p>Creative Medical Technology Holdings possesses numerous issued patents in the area of cellular therapy including patent no. 10,842,815 covering use of T regulatory cells for spinal disc regeneration, patent no. 9,598,673 covering stem cell therapy for disc regeneration, patent no. 10,792,310 covering regeneration of ovaries using endothelial progenitor cells and mesenchymal stem cells, patent no. 8,372,797 covering use of stem cells for erectile dysfunction, and patent no. 7,569,385 licensed from the <span class=\"xn-org\">University of California<\/span> covering a novel stem cell type. \u00a0<\/p>\n<p>&#8220;Given that our issued intellectual property covers multi-billion dollar markets, it is critical in our development plans to establish scientific mechanisms of action. By understanding how our products work at a cellular and molecular level, we feel we have an advantage when engaging Big Pharma in discussions for licensing\/partnering interactions.&#8221; <span class=\"xn-person\">Said Timothy Warbington<\/span>, President and CEO of the Company. <\/p>\n<p>The company intends to publish an update on the overall 2020 activities in the coming weeks. <\/p>\n<p>\n        <b>About Creative Medical Technology Holdings<\/b>\n      <\/p>\n<p>Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company specializing in stem cell technology in the fields of urology, neurology and orthopedics and trades on the OTC under the ticker symbol CELZ. For further information about the company, please visit\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3008751-1&amp;h=2896526939&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2910057-1%26h%3D667672444%26u%3Dhttp%253A%252F%252Fwww.creativemedicaltechnology.com%252F%26a%3Dwww.creativemedicaltechnology.com&amp;a=www.creativemedicaltechnology.com\" rel=\"nofollow noopener noreferrer\">www.creativemedicaltechnology.com<\/a>.<b>\u00a0<\/b><\/p>\n<p>\n        <b>Forward Looking Statements<\/b>\n      <\/p>\n<p>OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission&#8217;s website at\u00a0<a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3008751-1&amp;h=642481639&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2910057-1%26h%3D2959138883%26u%3Dhttp%253A%252F%252Fwww.sec.gov%252F%26a%3Dwww.sec.gov&amp;a=www.sec.gov\" rel=\"nofollow noopener noreferrer\">www.sec.gov<\/a>.<\/p>\n<p>\n        <span class=\"xn-person\">Timothy Warbington<\/span>, CEO\u00a0<br \/>CEO@ CreativeMedicalHealth.com<\/p>\n<p>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3008751-1&amp;h=3780546893&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2910057-1%26h%3D1131882491%26u%3Dhttps%253A%252F%252Fcreativemedicaltechnology.com%252F%26a%3DCreativemedicaltechnology.com&amp;a=Creativemedicaltechnology.com\" rel=\"nofollow noopener noreferrer\">Creativemedicaltechnology.com<\/a><br \/>\n        <br \/>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3008751-1&amp;h=3872208217&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2910057-1%26h%3D933268132%26u%3Dhttp%253A%252F%252Fwww.stemspine.com%252F%26a%3Dwww.StemSpine.com&amp;a=www.StemSpine.com\" rel=\"nofollow noopener noreferrer\">www.StemSpine.com<\/a><br \/>\n        <br \/>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3008751-1&amp;h=3437307578&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2910057-1%26h%3D1420064625%26u%3Dhttp%253A%252F%252Fwww.caverstem.com%252F%26a%3Dwww.Caverstem.com&amp;a=www.Caverstem.com\" rel=\"nofollow noopener noreferrer\">www.Caverstem.com<\/a><br \/>\n        <br \/>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3008751-1&amp;h=1667146767&amp;u=https%3A%2F%2Fc212.net%2Fc%2Flink%2F%3Ft%3D0%26l%3Den%26o%3D2910057-1%26h%3D2657420537%26u%3Dhttp%253A%252F%252Fwww.femcelz.com%252F%26a%3Dwww.Femcelz.com&amp;a=www.Femcelz.com\" rel=\"nofollow noopener noreferrer\">www.Femcelz.com<\/a>\n      <\/p>\n<p>\n        <sup>1<\/sup><br \/>\n        <a target=\"_blank\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=3008751-1&amp;h=4185165586&amp;u=https%3A%2F%2Fwww.jimmunol.org%2Fcontent%2F170%2F3%2F1304&amp;a=https%3A%2F%2Fwww.jimmunol.org%2Fcontent%2F170%2F3%2F1304\" rel=\"nofollow noopener noreferrer\">https:\/\/www.jimmunol.org\/content\/170\/3\/1304<\/a>\n      <\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder2\"><\/div>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=LA19682&amp;sd=2020-12-10\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"http:\/\/www.prnewswire.com\/news-releases\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy-301190255.html\">http:\/\/www.prnewswire.com\/news-releases\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy-301190255.html<\/a><\/p>\n<p>SOURCE  Creative Medical Technology Holdings, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=LA19682&amp;Transmission_Id=202012100745PR_NEWS_USPR_____LA19682&amp;DateId=20201210\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Clinical Stage Cell Therapy Company Reports Concurrent Modulation of T Regulatory Cells and Tolerogenic Dendritic Cells using Adoptive Cellular Therapy PR Newswire PHOENIX, Dec. 10, 2020 \/PRNewswire\/ &#8212;\u00a0Creative Medical Technology Holdings trading under the ticker symbol CELZ announced today its patent filing based on data covering utilization of the Company&#8217;s ImmCelz\u00ae product at generating what is termed in the field of immunology as &#8220;infectious tolerance.&#8221;\u00a0 Using an animal model of rheumatoid arthritis, investigators demonstrated administration of ImmCel\u00ae protected mice from immunologically mediated joint damage. Importantly, cells from treated mice were able to reverse disease when transferred to arthritic mice. Detailed scientific analysis revealed that ImmCelz\u00ae administration caused generation of T regulatory cells and tolerogenic dendritic cells.\u00a0 Both of these cell &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Creative Medical Technology Holdings files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz\u00ae Cellular Immunotherapy&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-397171","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Creative Medical Technology Holdings files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz\u00ae Cellular Immunotherapy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Creative Medical Technology Holdings files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz\u00ae Cellular Immunotherapy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Clinical Stage Cell Therapy Company Reports Concurrent Modulation of T Regulatory Cells and Tolerogenic Dendritic Cells using Adoptive Cellular Therapy PR Newswire PHOENIX, Dec. 10, 2020 \/PRNewswire\/ &#8212;\u00a0Creative Medical Technology Holdings trading under the ticker symbol CELZ announced today its patent filing based on data covering utilization of the Company&#8217;s ImmCelz\u00ae product at generating what is termed in the field of immunology as &#8220;infectious tolerance.&#8221;\u00a0 Using an animal model of rheumatoid arthritis, investigators demonstrated administration of ImmCel\u00ae protected mice from immunologically mediated joint damage. Importantly, cells from treated mice were able to reverse disease when transferred to arthritic mice. Detailed scientific analysis revealed that ImmCelz\u00ae administration caused generation of T regulatory cells and tolerogenic dendritic cells.\u00a0 Both of these cell &hellip; Continue reading &quot;Creative Medical Technology Holdings files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz\u00ae Cellular Immunotherapy&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-10T12:48:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/926061\/Creative_Medical_Technology_Holdings_Inc_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Creative Medical Technology Holdings files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz\u00ae Cellular Immunotherapy\",\"datePublished\":\"2020-12-10T12:48:09+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\\\/\"},\"wordCount\":568,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/926061\\\/Creative_Medical_Technology_Holdings_Inc_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\\\/\",\"name\":\"Creative Medical Technology Holdings files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz\u00ae Cellular Immunotherapy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/926061\\\/Creative_Medical_Technology_Holdings_Inc_Logo.jpg\",\"datePublished\":\"2020-12-10T12:48:09+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/926061\\\/Creative_Medical_Technology_Holdings_Inc_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/926061\\\/Creative_Medical_Technology_Holdings_Inc_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Creative Medical Technology Holdings files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz\u00ae Cellular Immunotherapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Creative Medical Technology Holdings files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz\u00ae Cellular Immunotherapy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\/","og_locale":"en_US","og_type":"article","og_title":"Creative Medical Technology Holdings files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz\u00ae Cellular Immunotherapy - Market Newsdesk","og_description":"Clinical Stage Cell Therapy Company Reports Concurrent Modulation of T Regulatory Cells and Tolerogenic Dendritic Cells using Adoptive Cellular Therapy PR Newswire PHOENIX, Dec. 10, 2020 \/PRNewswire\/ &#8212;\u00a0Creative Medical Technology Holdings trading under the ticker symbol CELZ announced today its patent filing based on data covering utilization of the Company&#8217;s ImmCelz\u00ae product at generating what is termed in the field of immunology as &#8220;infectious tolerance.&#8221;\u00a0 Using an animal model of rheumatoid arthritis, investigators demonstrated administration of ImmCel\u00ae protected mice from immunologically mediated joint damage. Importantly, cells from treated mice were able to reverse disease when transferred to arthritic mice. Detailed scientific analysis revealed that ImmCelz\u00ae administration caused generation of T regulatory cells and tolerogenic dendritic cells.\u00a0 Both of these cell &hellip; Continue reading \"Creative Medical Technology Holdings files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz\u00ae Cellular Immunotherapy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-10T12:48:09+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/926061\/Creative_Medical_Technology_Holdings_Inc_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Creative Medical Technology Holdings files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz\u00ae Cellular Immunotherapy","datePublished":"2020-12-10T12:48:09+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\/"},"wordCount":568,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/926061\/Creative_Medical_Technology_Holdings_Inc_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\/","name":"Creative Medical Technology Holdings files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz\u00ae Cellular Immunotherapy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/926061\/Creative_Medical_Technology_Holdings_Inc_Logo.jpg","datePublished":"2020-12-10T12:48:09+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/926061\/Creative_Medical_Technology_Holdings_Inc_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/926061\/Creative_Medical_Technology_Holdings_Inc_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/creative-medical-technology-holdings-files-patent-on-induction-of-infectious-tolerance-by-ex-vivo-reprogrammed-immune-cells-utilizing-immcelz-cellular-immunotherapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Creative Medical Technology Holdings files Patent on Induction of Infectious Tolerance by Ex Vivo Reprogrammed Immune Cells Utilizing ImmCelz\u00ae Cellular Immunotherapy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/397171","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=397171"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/397171\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=397171"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=397171"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=397171"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}